Prostate cancer（PCa）is most common among American and European males. Advanced PCa patients are witnessed to be effectively treated with androgen deprivation therapy（ADT）at the preliminary stage and it eventually develops to the castration⁃resistant prostate cancer（CRPC），which results in poor prognosis. In recent years，immune checkpoint inhibitors（ICIs）have been successfully applied in the treatment of advanced PCa. In this paper，we have reviewed the literature on ICIs′ role in the treatment of advanced PCa，and discussed its development directions and application prospects.